Acquired Resistance to KRAS G12C Inhibition in Cancer

Mark M. Awad; Shengwu Liu; Igor I. Rybkin; Kathryn C. Arbour; Julien Dilly; Viola W. Zhu; Melissa L. Johnson; Rebecca S. Heist; Tejas Patil; Gregory J. Riely; Joseph O. Jacobson; Xiaoping Yang; Nicole S. Persky; David E. Root; Kristen E. Lowder; Han-Rong Feng; Shannon S. Zhang; Kevin M. Haigis; Yin P Hung; Lynette M. Sholl; Brian M. Wolpin; Julie Wiese; Jason Christiansen; Jessica Lee; Alexa B. Schrock; Lee P. Lim; Kavita Garg; Mark Li; Lars D. Engstrom; Laura Waters; J. David Lawson; Peter Olson; Piro Lito; Sai-Hong I. Ou; James G. Christensen; Pasi A. Jänne; Andrew J. Aguirre

doi:10.1056/nejmoa2105281

Abstract

Diverse genomic and histologic mechanisms impart resistance to covalent KRASG12C inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer. (Funded by Mirati Therapeutics and others; ClinicalTrials.gov number, NCT03785249.).

Affiliated Institutions

Related Publications

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Cory M. Johannessen , Jesse S. Boehm , So Young Kim +32 more

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50–70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V...

2010 Nature 1436 citations

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Georgia Hatzivassiliou , Kyung Song , Ivana Yen +18 more

Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic...

2010 Nature 1590 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva , Adina Vultur , John Tayu Lee +18 more

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF...

2010 Cancer Cell 1218 citations

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Nikhil Wagle , W. Marston Linehan , Michael F. Berger +9 more

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted anticancer agents should speed the development of treatment strategies with lasting cli...

2011 Journal of Clinical Oncology 988 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian , Hubing Shi , Qi Wang +13 more

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel clas...

2010 Nature 2132 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 25
Pages: 2382-2393
Citations: 999
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Acquired Resistance to KRAS G12C Inhibition in Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

999

OpenAlex

Cite This

APA Style

                            
                                
                                    Mark M. Awad, 
                                
                                    Shengwu Liu, 
                                
                                    Igor I. Rybkin
                                
                                et al.
                            
                            (2021). 
                            Acquired Resistance to KRAS <sup>G12C</sup> Inhibition in Cancer. 
                            New England Journal of Medicine
                            , 384
                            (25)
                            , 2382-2393.
                            https://doi.org/10.1056/nejmoa2105281
                        

Identifiers

DOI: 10.1056/nejmoa2105281